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Abstract: Background: Randomised trials have shown that alteplase 
improves the odds of a good stroke outcome when delivered within 4.5 
hours of acute ischaemic stroke. Alteplase also increases the risk of 
intracerebral haemorrhage, but the factors determining the proportional 
and absolute risks are uncertain. 
Methods: We used data from the Stroke Thrombolysis Trialists' (STT) meta-
analysis of individual patient data from 9 randomised trials of alteplase 
versus placebo (or open control) involving 6,756 patients. We pre-
specified assessment of 3 definitions of intracerebral haemorrhage: type 
2 parenchymal haemorrhage (PH-2) within 7 days; SITS-MOST haemorrhage 
within 24-36 hours (PH-2 with at least 4 point deterioration in NIHSS); 
and fatal intracerebral haemorrhage within 7 days. We used logistic 
regression, stratified by trial, to model the log odds of intracerebral 
haemorrhage on allocation to alteplase, treatment delay, age, and stroke 
severity. Exploratory analyses assessed mortality after intracerebral 
haemorrhage and examined the absolute risks of intracerebral haemorrhage 
in the context of functional outcome at 90-180 days.  
Findings: Alteplase increased the odds of PH-2 haemorrhage (231/3391 
[6.8%] among patients allocated alteplase vs 44/3365 [1.3%] among 
patients allocated control; odds ratio [OR] 5.55, 95% CI 4.01-7.70; 
absolute excess 5.5% [95% CI 4.6% - 6.4%]); SITS-MOST haemorrhage 
(124/3391 [3.7%] vs 19/3365 [0.6%]; OR 6.67, 4.11-10.84; absolute excess 
3.1% [2.4% - 3.8%]); and of fatal intracerebral haemorrhage (91/3391 
[2.7%] vs 13/3365 [0.4%]; OR 7.14, 3.98-12.79; absolute excess 2.3% [1.7% 
- 2.9%]). However defined, the proportional increase in intracerebral 
haemorrhage was similar irrespective of treatment delay, age or baseline 
stroke severity, but the absolute excess risk of intracerebral 
haemorrhage increased with increasing stroke severity: for SITS-MOST 
intracerebral haemorrhage the absolute excess risk ranged from 1.5% (95% 
CI 0.8-2.6%) for strokes with NIHSS 0-4 to 3.7% (95% CI 2.1-6.3%) for 
NIHSS ≥22 (trend p=0.01).  For those treated within 4.5 hours, the 
absolute increase in the proportion (6.8%) achieving a modified Rankin 
score of 0 or 1 (excellent outcome) exceeded the absolute increase in 
risk of fatal intracerebral haemorrhage (2.2%) and the increased risk of 
any death within 90 days (0.9%).  
Interpretation: Among patients treated with alteplase the net outcome is 
predicted both by time to treatment (with faster time increasing the 
proportion achieving an excellent outcome) and stroke severity (with more 
severe stroke increasing the absolute risk of intracerebral haemorrhage). 
Although, on average, within 4.5 hours of stroke, the probability of 
achieving an excellent outcome clearly exceeds the risk of death, early 
treatment is especially important for those with severe strokes. 
 
 
 
 
 
  1 
What are the risks of intracerebral haemorrhage due to alteplase after acute ischaemic 
stroke? Results from an individual patient data meta-analysis of randomised trials 
Dr. William N Whiteley BM BCh,a Dr. Jonathan Emberson PhD,b Prof. Kennedy R Lees MD,c Lisa 
Blackwell BSc, b Prof. Gregory Albers, MD,d Prof. Erich Bluhmki,e PhD, Prof. Thomas Brott,f MD, Geoff 
Cohen, MSc,a Prof. Stephen Davis,g MD, Prof. Geoffrey Donnan, MD,h Dr. James Grotta, MD,i Prof. 
George Howard, DrPH,j Prof. Markku Kaste, MD,k Dr. Masatoshi Koga, MD,l Prof. Rüdiger von 
Kummer,m Prof. Maarten G Lansberg, MD,d Prof. Richard I Lindley, MD,n Prof Patrick Lyden,o Prof. 
Jean Marc Olivot, MD,p Prof. Mark Parsons, MD,q Prof. Danilo Toni, MD,r Prof. Kazunori Toyoda, MD,l 
Prof. Nils Wahlgren, MD,s Prof. Joanna Wardlaw, MD,a Prof. Gregory J del Zoppo, MD,t Prof. Peter 
Sandercock DM,a Prof. Werner Hacke MD,u Prof. Colin Baigent BM BChb 
on behalf of the Stroke Thrombolysis Trialists’ (STT) Collaboration 
 
Correspondence to: 
Professor Colin Baigent 
Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), 
Nuffield Department of Population Health 
Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK 
Email:  STT@ctsu.ox.ac.uk 
Phone: +44 1865 743743 
Fax: +44 1865 743985 
 
Word count: Abstract (410); Main text (3636) 
 
 
Manuscript
  2 
a. University of Edinburgh, Edinburgh, UK 
b. Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, Oxford, UK 
c. University of Glasgow, Glasgow, UK 
d. Stanford University, Stanford, CA, USA 
e. Boehringer Ingelheim, Ingelheim, Germany 
f. Mayo Clinic, Jacksonville, FL, USA 
g. University of Melbourne, Melbourne, VIC, Australia 
h. The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia 
i. Memorial Hermann Hospital, Houston, TX , USA 
j. University of Alabama, Birmingham, AL, USA 
k. Clinical Neurosciences, Neurology, University of Helsinki and Department of Neurology, 
Helsinki University Hospital, Helsinki, Finland 
l. National Cerebral and Cardiovascular Centre, Suita, Japan 
m. Technische Universität, Dresden, Germany 
n. The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia 
o. Department of Neurology, Cedars-Sinai, Los Angeles, CA, USA 
p. Centre Hospitalier Universitaire de Toulouse, France 
q. University of Newcastle, Newcastle, NSW, Australia 
r. Sapienza University, Rome, Italy 
s. Karolinska Institutet, Clinical Neuroscience, Stockholm, Sweden 
t. University of Washington, Seattle, WA, USA 
u. University of Heidelberg, Heidelberg, Germany 
  3 
Abstract 
Background: Randomised trials have shown that alteplase improves the odds of a good stroke 
outcome when delivered within 4.5 hours of acute ischaemic stroke. Alteplase also increases the risk 
of intracerebral haemorrhage, but the factors determining the proportional and absolute risks are 
uncertain. 
Methods: We used data from the Stroke Thrombolysis Trialists’ (STT) meta-analysis of individual 
patient data from 9 randomised trials of alteplase versus placebo (or open control) involving 6,756 
patients. We pre-specified assessment of 3 definitions of intracerebral haemorrhage: type 2 
parenchymal haemorrhage (PH-2) within 7 days; SITS-MOST haemorrhage within 24-36 hours (PH-2 
with at least 4 point deterioration in NIHSS); and fatal intracerebral haemorrhage within 7 days. We 
used logistic regression, stratified by trial, to model the log odds of intracerebral haemorrhage on 
allocation to alteplase, treatment delay, age, and stroke severity. Exploratory analyses assessed 
mortality after intracerebral haemorrhage and examined the absolute risks of intracerebral 
haemorrhage in the context of functional outcome at 90-180 days.  
Findings: Alteplase increased the odds of PH-2 haemorrhage (231/3391 [6.8%] among patients 
allocated alteplase vs 44/3365 [1.3%] among patients allocated control; odds ratio [OR] 5.55, 95% CI 
4.01–7.70; absolute excess 5.5% [95% CI 4.6% - 6.4%]); SITS-MOST haemorrhage (124/3391 [3.7%] vs 
19/3365 [0.6%]; OR 6.67, 4.11-10.84; absolute excess 3.1% [2.4% - 3.8%]); and of fatal intracerebral 
haemorrhage (91/3391 [2.7%] vs 13/3365 [0.4%]; OR 7.14, 3.98–12.79; absolute excess 2.3% [1.7% - 
2.9%]). However defined, the proportional increase in intracerebral haemorrhage was similar 
irrespective of treatment delay, age or baseline stroke severity, but the absolute excess risk of 
intracerebral haemorrhage increased with increasing stroke severity: for SITS-MOST intracerebral 
haemorrhage the absolute excess risk ranged from 1.5% (95% CI 0.8-2.6%) for strokes with NIHSS 0-4 
to 3.7% (95% CI 2.1-6.3%) for NIHSS ≥22 (trend p=0.01).  For those treated within 4.5 hours, the 
absolute increase in the proportion (6.8%) achieving a modified Rankin score of 0 or 1 (excellent 
outcome) exceeded the absolute increase in risk of fatal intracerebral haemorrhage (2.2%) and the 
increased risk of any death within 90 days (0.9%).  
Interpretation: Among patients treated with alteplase the net outcome is predicted both by time to 
treatment (with faster time increasing the proportion achieving an excellent outcome) and stroke 
severity (with more severe stroke increasing the absolute risk of intracerebral haemorrhage). 
Although, on average, within 4.5 hours of stroke, the probability of achieving an excellent outcome 
clearly exceeds the risk of death, early treatment is especially important for those with severe 
strokes. 
Funding: UK MRC, BHF, University of Glasgow, University of Edinburgh. 
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Introduction 1 
The Stroke Thrombolysis Trialists’ (STT) Collaboration has previously shown, in a meta-analysis of 2 
individual participant data from 9 trials of alteplase versus placebo (or open control), that alteplase 3 
significantly improves the odds of an excellent outcome (i.e., a modified Rankin score [mRS] of 0 or 4 
1) when delivered within 4.5 hours of the onset of ischaemic stroke.1 However, alteplase increases 5 
the risk of intracerebral haemorrhage within 48 hours of administration,1 and variations in the 6 
absolute risks of such haemorrhage according to clinical presentation (eg, stroke severity) may 7 
influence the longer term outcome.  Recent commentaries have drawn attention to a lack of reliable 8 
information about the hazards of alteplase and how they relate to benefits among different groups 9 
of patients, particularly those presenting more than 3 hours after stroke onset.2,3 In the UK, the 10 
Medicines and Healthcare Products Regulatory Agency (MHRA) expert working group considered, in 11 
strict confidence, these analyses from the STT Collaboration on the benefits and risks of alteplase as 12 
part of its review of the market authorisation for alteplase in acute ischaemic stroke.4 13 
 14 
Since there are strong inter-relationships between prognostic variables among the trials included in 15 
the STT database (for example, patients treated earlier tended to be older and to have had more 16 
severe strokes), an assessment of benefit and harm can only be performed reliably using 17 
multivariable models applied to individual participant data. The STT’s published protocol5 outlined a 18 
range of secondary analyses that were to be conducted in addition to the main analysis.1 The aim of 19 
the present report is to describe the results of secondary analyses assessing the proportional and 20 
absolute effects of alteplase on the risk of intracerebral haemorrhage and of mortality in different 21 
types of patients. We also explore how such variations might influence the net effects of alteplase by 22 
90-180 days after stroke. 23 
24 
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Methods 25 
Study design 26 
The methods of the Stroke Thrombolysis Trialists’ (STT) Collaboration have been described in detail 27 
in the published protocol5 and in the main report of the primary analysis.1 Briefly, we sought 28 
individual participant data from all completed randomised phase 3 trials of intravenous alteplase in 29 
acute ischaemic stroke. Since a systematic review of trials of thrombolysis had been updated in 2013 30 
6 we identified potentially eligible trials from that review and by enquiry among active trialists and 31 
the manufacturer of alteplase used in all participating trials (Boehringer Ingelheim, Ingelheim, 32 
Germany).5 We analysed participants in the group to which they were randomly allocated (‘intention 33 
to treat’).  34 
Outcomes 35 
The main outcome of interest in the current analysis was intracerebral haemorrhage, which was 36 
defined in three ways:  37 
(i) parenchymal haemorrhage type 2 (PH-2) by 7 days after randomisation: defined as dense 38 
blood clot(s) exceeding 30% of the infarct volume with significant space-occupying effect 39 
seen on brain imaging, whether within or remote from the infarct.7 For patients from IST-3,8 40 
in which PH-2 defined solely on radiological findings was not a pre-specified secondary 41 
outcome, we approximated it by a report from the IST-3 blinded CT-reading panel of 42 
‘significant brain parenchymal haemorrhage, local or remote from the infarct, or significant 43 
diffuse haemorrhagic transformation of an infarct on brain imaging’;   44 
(ii) Safe Implementation of Thrombolysis in Stroke Monitoring Study’s (SITS-MOST) 45 
haemorrhage9 defined as PH-2 on imaging with an increase of 4 NIHSS points or more from 46 
baseline (or the lowest point in the first 24 hours) or that led to death within 36 hours of 47 
treatment. In the third international stroke trial (IST-3), we approximated the SITS-MOST 48 
definition by the occurrence within 24 hours of ‘clinically significant deterioration or death, 49 
together with evidence of either significant brain parenchymal haemorrhage (local or distant 50 
from the infarct) or significant haemorrhagic transformation of an infarct on brain imaging 51 
which, in the judgement of the blinded adjudication panel, was likely to have worsened mass 52 
effect or contributed to the burden of brain damage’; and  53 
(iii) fatal intracerebral haemorrhage, defined as PH-2 (or its approximation in IST-3) 54 
confirmed by imaging (or autopsy) and death within 7 days of randomisation.  55 
 56 
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The timing of brain imaging to detect intracerebral haemorrhage varied slightly across the 57 
participating trials. The protocol of each trial mandated imaging at approximately 24 hours post-58 
randomisation and additional brain imaging if neurological deterioration occurred. Further routine 59 
brain imaging was performed at 3-5 days in the Echoplanar Imaging Thrombolytic Evaluation Trial 60 
(EPITHET),10 at 1 week in National Institutes of Neurological Diseases and Stroke (NINDS) A and B11 61 
and in European Cooperative Acute Stroke Study (ECASS) I, II, and III;7,12,13, and at 23-37 days in 62 
Alteplase Thrombolysis for Acute Non-interventional Therapy in Ischemic Stroke  (ATLANTIS) A and 63 
B.14,15  64 
 65 
Analyses of the effect of alteplase on death from all causes within 90 days, both overall and when 66 
separated by period of follow-up and treatment delay, have been published previously.1 In post-hoc 67 
analyses of mortality for the current analysis, we subclassified deaths as: “deaths preceded by 68 
clinically significant intracerebral haemorrhage” (defined as fatal ICH within 7 days or death 69 
following SITS-MOST haemorrhage), and all other deaths.  70 
 71 
We analysed the modified Rankin score (mRS) to define stroke outcome at 3-6 months. We defined 72 
an ‘excellent’ stroke outcome as mRS of 0–1 (ie, symptom-free or residual symptoms with no loss of 73 
activity), and a very poor stroke outcome as mRS of 5–6 (i.e. bed-bound or dead) at 3–6 months. In 74 
IST-3, mRS was reported at 6 rather than 3 months. Therefore, for consistency between the 75 
previously published analyses of 90-day mortality and the odds ratio estimates for mRS 0-5 vs 6 in 76 
the current analysis, we made the simplifying assumption that IST-3 patients who died between 91 77 
days and 6 months (125 [4.1%] IST-3 participants) had an mRS of 5 at 90 days. 1 78 
 79 
Statistical analysis 80 
We used logistic regression, stratified by trial, to model the common linear dependence of the log 81 
odds of intracerebral haemorrhage on allocation to alteplase, treatment delay, age, baseline stroke 82 
severity (National Institutes of Health Stroke Scale [NIHSS]) and interactions between allocation to 83 
alteplase and each of these other baseline covariates. Alternative hierarchical models that allowed 84 
for random effects to operate at the trial level gave virtually identical results. Treatment delay, age 85 
and stroke severity were all handled as linear variables. Analyses that considered quadratic risk-86 
relationships for stroke severity were not informative over the models that simply considered a 87 
linear term, and are therefore not reported. In addition to such ‘continuous’ analyses, regression 88 
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models that handled each baseline covariate in pre-defined categories of treatment delay (≤3.0 89 
hours, >3 to ≤4.5 hours, >4.5 hours), age (≤80, >80 years) and stroke severity (NIHSS ≤4, 5-10, 11-15, 90 
16-21, ≥22) were also employed. Missing 6 month modified Rankin data in IST-3 were imputed from 91 
seven-day assessments using an algorithm that was found to work well among patients who had 92 
both measurements.5 Assessment of whether treatment delay, age, stroke severity or trial modified 93 
(individually or jointly) the overall effect of alteplase on particular outcomes was based on the 94 
statistical significance of the relevant treatment interactions using likelihood ratio tests (i.e. through 95 
comparison of minus twice the log-likelihood statistic between appropriate “nested” models). Trial-96 
by treatment interactions were used to assess whether there were important differences in the odds 97 
of intracerebral haemorrhage with alteplase between the 9 trials, and between IST-3 (with open 98 
control) and all other (placebo-controlled) trials combined.   99 
 100 
Kaplan-Meier cumulative mortality curves during the first 90 days were calculated for patients 101 
allocated alteplase and patients allocated control (crudely pooling across all trials). Subsequently, 102 
trial-stratified Cox regression was used to estimate the average mortality hazard ratio within 90 days 103 
for ‘deaths preceded by clinically significant intracerebral haemorrhage’ and for all other deaths, 104 
with the time to event/censoring for both outcomes set as the earliest of day 90 or the date of 105 
death.  106 
 107 
Stroke severity and treatment delay are both important determinants of stroke outcome for patients 108 
given alteplase. However, as previously reported, stroke severity and treatment delay were 109 
correlated in the included trials.1 Therefore, to prevent treatment delay from confounding the 110 
observed mRS distribution when treated patients were subdivided by their baseline stroke severity 111 
(NIHSS ≤4; 5-10; 11-15; 16-21 and ≥22), we compared, for each baseline NIHSS group, the observed 112 
mRS distribution for control patients with the expected distribution if given alteplase within 3 or 113 
within 4.5 hours. This expected distribution was obtained by applying the overall odds ratios for each 114 
mRS dichotomy (ie, mRS 0 vs 1-6, mRS 0-1 vs 2-6, etc.) within a given time window (≤4.5 hours, <3 115 
hours or 3-4.5 hours) to the observed mRS distribution at 3-6 months among control-allocated 116 
patients. Similarly, the estimates of absolute excess risk subdivided by a given characteristic 117 
(treatment delay, age or stroke severity) were obtained by applying the overall odds ratio estimates 118 
(and their confidence limits) to the control rates that would have been expected for that subgroup 119 
had average levels of the other two characteristics applied.  120 
 121 
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 122 
All estimates of treatment effect are provided with their 95% confidence intervals with p-values 123 
considered conventionally statistically significant, without allowance for multiple testing, at the 5% 124 
significance level. Analyses were done with SAS version 9.3 (SAS Institute, Cary) and R version 2.11.1 125 
(www.R-project.org). 126 
 127 
Role of the funding source 128 
The funders had no role in study design, data collection, data analysis, data interpretation, or writing 129 
of the report. The secretariat had full access to all the data and responsibility for the decision to 130 
submit for publication. 131 
132 
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Results  133 
Data were available from 6756 participants in 9 trials of intravenous alteplase versus control 134 
(webtable 1). Baseline data on treatment delay, age and baseline NIHSS were complete for almost all 135 
participants (6602/6756, 98%). Individual participant data were sought from  an additional 5 trials16–136 
20 involving 270 participants, which reported a total of 18 patients with intracerebral haemorrhage 137 
(11 alteplase versus 7 control), but were either not available or, in one case,18 the authors could not 138 
be contacted.  139 
Overall, 275 participants had a PH-2 haemorrhage within 7 days of treatment (38% [39% alteplase vs 140 
30% control] fatal within 7 days), of which 52% were SITS-MOST haemorrhages (41% [40% vs 47%] 141 
fatal within 7 days). After adjusting for age, treatment delay and stroke severity, alteplase increased 142 
the odds of intracerebral haemorrhage by a factor of about 6 to 7, depending on the definition used: 143 
PH-2 haemorrhage: 231/3391 (6.8%) vs 44/3365 (1.3%); OR 5.55, 95% CI 4.01–7.70; SITS-MOST 144 
haemorrhage 124/3391 (3.7%) vs 19/3365 (0.6%); OR 6.67, 4.11–10.84; and fatal intracerebral 145 
haemorrhage within 7 days 91/3391 (2.7%) vs 13/3365 (0.4%); OR 7.14, 3.98–12.79 (figure 1). These 146 
odds ratios were similar after adjusting for other baseline variables recorded and available in the 147 
data provided (prior stroke/TIA, prior diabetes, antiplatelet use, weight and systolic blood pressure 148 
at randomisation, data not shown). There was no evidence that the odds ratios for any of the 149 
definitions of intracerebral haemorrhage differed between trials, or between IST-3 (which had open 150 
control) and the 8 placebo-controlled trials (all heterogeneity p-values >0.05, webfigure 1). The 151 
proportion of patients with PH-2 haemorrhages who died by 7 days was also similar in IST-3 (62/159, 152 
[39%]) and in the other 8 (placebo-controlled) trials (42/116, [36%]).  153 
For each type of intracerebral haemorrhage, the proportional effects of alteplase were similar 154 
irrespective of time to treatment, age or stroke severity (webfigures 2-4; p-values for interaction all 155 
>0.05). The estimated absolute excess risks were similar irrespective of time to treatment and age, 156 
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but there was a trend towards larger absolute excess risks with increasing stroke severity for PH-2 157 
haemorrhage (p<0.0001; webfigure 5), fatal intracerebral haemorrhage (p=0.0002; webfigure 6) and 158 
SITS-MOST haemorrhage (p=0.0101; figure 2). For SITS-MOST intracerebral haemorrhages (ie, 159 
clinically significant bleeds in which there was both radiological evidence of bleeding and worsening 160 
symptoms within 24-36 hours after treatment), the absolute excess risk over control increased from 161 
1.5% (95% CI 0.8-2.6%) among those with mild strokes (baseline NIHSS 0–4) to 3.7% (95% CI 2.1-162 
6.3%) in patients with NIHSS ≥22 (figure 2). 163 
Cause of death was not widely available in participating trials, but we conducted exploratory 164 
analyses to assess the 90-day risks of ‘death preceded by clinically significant intracerebral 165 
haemorrhage’ and of all other deaths. Among all trial participants, allocation to alteplase was 166 
associated with a significant increase in the risk of a death preceded by clinically significant 167 
intracerebral haemorrhage within 90 days (118 [3.5%] vs 14 [0.4%]; HR 8.52, 4.89-14.82; figure 3). 168 
Such deaths were, however, offset by non-significantly fewer deaths among people dying who had 169 
not experienced such a haemorrhage (490 [14.5%] vs 542 [15.9%]; HR 0.92, 95% CI 0.82-1.04; figure 170 
3). An analysis that defined clinically significant haemorrhage by the radiological appearance of a 171 
PH2 haemorrhage, rather than by the SITS-MOST definition, gave similar results (webfigure 8). 172 
 173 
Since the estimated absolute excess risk of intracerebral haemorrhage increased incrementally 174 
within the 5 pre-specified categories of stroke severity, we assessed the impact of this trend on the 175 
expected distribution of mRS scores at 90 days among all patients treated within 4.5 hours (on 176 
average, at 3 hours and 20 minutes) by applying the odds ratio for each mRS transition to the control 177 
population (figure 4 and 5). Among patients with the mildest strokes (NIHSS 0–4), alteplase would be 178 
expected to result in an absolute increase in excellent outcome of 8.0% (95% CI 4.5-11.1), and to 179 
reduce the absolute risk of very poor outcome by 0.1% (95% CI -0.6-0.8; 0.3% reduction in severe 180 
disability [mRS 5] and 0.2% excess of death). For the most severe strokes (NIHSS ≥22), the 181 
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corresponding amounts were a 1.0% (95% CI 0.5-1.5) absolute increase in excellent outcome and a 182 
0.6% reduction in very poor outcome (95% CI -2.3-4.1; 2.8% reduction in severe disability and 2.1% 183 
excess of death).184 
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Discussion 185 
Within the 9 trials studied, alteplase resulted in approximately 6 to 7 times the odds of intracerebral 186 
haemorrhage within the first 7 days, which was similar irrespective of treatment delay, age and 187 
stroke severity. In these trials the underlying risk of intracerebral haemorrhage without alteplase 188 
increased with stroke severity, which is consistent with a systematic review of 55 observational 189 
studies in which each 1 point increment in the NIHSS was associated with an 8% (95% CI 6-11%) 190 
increase in the odds of intracerebral haemorrhage (p<0.001).21 In the absence of heterogeneity of 191 
the odds ratio for haemorrhage, therefore, the absolute excess risk of intracerebral haemorrhage 192 
was higher among those with more severe strokes. Overall, among all patients, alteplase resulted in 193 
a 2.3% absolute excess of fatal intracerebral haemorrhage during the first week (Figure 1). After the 194 
first week, deaths preceded by ICH remained elevated among those allocated alteplase (Figure 3), 195 
perhaps due to conditions associated with chronic immobility (eg pneumonia). By contrast, during 196 
the first 90 days, there were non-significantly fewer other deaths among alteplase-allocated 197 
patients, perhaps owing to the beneficial effects of alteplase on functional outcome.   198 
 199 
Taken together, the present analyses and our previous report show that, when given within 4.5 200 
hours, alteplase is associated with an early hazard due to intracerebral haemorrhage but a later 201 
benefit in terms of less disability, and this study raises the hypothesis that there is a lower risk of 202 
death among those not experiencing an intracerebral haemorrhage. This pattern is analogous to 203 
many surgical procedures, eg carotid endarterectomy, where there is an early surgical hazard 204 
followed by a later survival benefit in selected patients22,23 and the balance of hazard and benefit 205 
among particular types of patients determines their net clinical outcome. 206 
 207 
The net effects of alteplase among particular types of patients are best represented by the predicted 208 
shift in the distribution of modified Rankin Scores among patients allocated to alteplase and control. 209 
  10 
Our previous analyses indicated that the benefits of alteplase diminish with increasing treatment 210 
delay, whilst the present analyses indicate that the absolute excess risk of intracerebral 211 
haemorrhage increases with stroke severity. Our exploratory analyses suggest that these two 212 
variables help determine the net effects of alteplase in particular patients. In particular, they may 213 
help to explain the observation in our previous report1 that there was a non-significant trend 214 
towards a larger relative increase in 90 day mortality among those treated later. Although there 215 
were limited data in the 3-4.5 hour group, it may be hypothesised that the observed patterns are 216 
due to the shifting balance between (i) an early increase in mortality from intracerebral 217 
haemorrhage (which is of similar magnitude irrespective of delay) and (ii) reduced mortality due to 218 
salvaged brain tissue among those treated early, with the magnitude of this benefit diminishing as 219 
delay increases (ie, ‘time is brain’). 220 
 221 
There is a need for improved representations of the benefits and risks of alteplase, building on those 222 
developed previously24–27, to better equip clinicians in discussions with patients and their family 223 
members. Figure 4 and webfigures 7a and 7b have the inherent limitation that they do not directly 224 
represent the additional risks of fatal intracerebral haemorrhage. An alternative example of a 225 
possible representation of the expected effects of alteplase on the distribution of mRS scores, 226 
subdivided by stroke severity, is shown in Figure 5. Each cell represents a hypothetical group of 100 227 
typical patients with an ischaemic stroke of given severity, with colours indicating a gradation of mRS 228 
scores at 3-6 months after stroke from excellent outcome (red circles, mRS 0-1) through to very poor 229 
outcome (mRS 5-6). Fatal intracerebral haemorrhage is marked by a purple circle with a cross.  From 230 
this figure, a patient can see, in their particular case, the expected impact of being given alteplase, 231 
since a comparison of left (untreated) and right (treated) cells shows both the expected shift in mRS 232 
outcomes and the risk associated with intracerebral haemorrhage. Further development and 233 
refinement of the representation in figure 5 is now needed to provide a useful tool for clinicians. 234 
  11 
 235 
Recent trials have demonstrated that intra-arterial thrombectomy in addition to intravenous 236 
thrombolysis leads to improved outcomes28–32 among those with large artery ischaemic stroke and 237 
documented proximal arterial occlusion, which may help to improve the ratio of benefit to risk by 238 
magnifying benefit through improved salvage of brain tissue. Alternatively, it may be possible to 239 
improve this ratio by reducing the risk of intracerebral haemorrhage with intravenous thrombolytic 240 
therapy, for example, by the use of tenecteplase as an alternative to alteplase33,34, use of a lower 241 
dose of alteplase (0.6mg/kg),35 or by targeting thrombolysis  based on neuroimaging appearances.31  242 
 243 
Although our analyses provide a general guide to the effects of alteplase in different types of 244 
patients, there are a number of potential limitations: First, and most importantly, despite having 245 
access to individual participant data from 9 trials in almost 7000 patients with acute ischaemic 246 
stroke, there were relatively small numbers of outcomes with which to examine treatment effects in 247 
different patient subgroups.32 Whilst recognising that there is a need to provide better information 248 
for doctors and patients, it is important that treatment decisions take account both of statistical 249 
uncertainty and of the possibility that different patients and their families may reach different 250 
decisions when presented with the same data on expected outcomes. The second limitation was 251 
that the methods employed by the Third International Stroke Trial (IST-3) differed in several respects 252 
to the other trials. It lacked a placebo control, raising the potential of biased reporting if there was a 253 
greater tendency to investigate possible intracerebral haemorrhage in the alteplase arm. However, 254 
alteplase increased the odds of intracerebral haemorrhage to a similar extent in IST-3 and in other 255 
trials (webfigure 1), suggesting that any bias due to the open nature of IST3 was small. The IST3 trial 256 
also did not record PH-2 haemorrhages or SITS-MOST haemorrhages, but defined equivalent 257 
categories. In the future, any such limitations caused by different symptomatic haemorrhage 258 
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definitions and classifications may be mitigated by the use of the recent Heidelberg classification of 259 
intracerebral bleeding events.39  260 
 261 
A third limitation was that we did not have cause of death available, but could only examine the 262 
effects of alteplase on deaths that followed a haemorrhage. Our data strongly suggest, however, 263 
that most early deaths following a PH2 haemorrhage were likely to be due to the haemorrhage. In 264 
particular, the increased risk of death from any cause by 7 days (absolute excess 2.2%)1 is virtually 265 
identical to the increased risk of those deaths that followed a PH2 haemorrhage (2.3%) (Figure 1). In 266 
addition, death preceded by clinically significant haemorrhage remained elevated after the first 267 
week (Figure 3). The most likely explanation for these large mortality differences is that 268 
haemorrhage led to death in almost all such cases (either directly, or after withdrawal of medical 269 
intervention), since the alternative explanation – that alteplase-allocated patients were at least 7 270 
times more likely than control-allocated patients to die from causes unrelated to the bleed – seems 271 
highly implausible given their similar prognostic scores at randomization and the lack of any other 272 
known hazard of alteplase. 273 
 274 
Finally, we were limited in the extent to which we could evaluate the effect of other potential risk 275 
factors, such as blood glucose and blood pressure control, that have previously been associated with 276 
increased bleeding risk after alteplase administration, and nor could we assess the effects of 277 
alteplase on less severe intracerebral haemorrhage since the requisite data were not consistently 278 
available. 279 
 280 
 281 
Conclusion 282 
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Although alteplase increases the early risk of haemorrhagic stroke, when given within 4.5 hours the 283 
proportion of patients experiencing an excellent outcome exceeded the proportion dying from 284 
intracerebral haemorrhage. The greatest absolute risk of intracerebral haemorrhage after alteplase 285 
is experienced by those with the most severe strokes, among whom prompt treatment is essential in 286 
order to achieve worthwhile benefit. 287 
  288 
  14 
Contributors 289 
WH and EB had the original idea for this meta-analysis and implemented data definitions in 2004; 290 
KRL and EB refined the approach in 2010; CB, PS, and JW had the idea for this cycle of the meta-291 
analysis and all authors contributed to the subsequent study protocol and statistical analysis plan. All 292 
authors contributed either to the acquisition of the original trial data or the creation of the 293 
combined dataset. JE and LB did the statistical analysis. WW wrote the first draft of the report. All 294 
authors contributed to the interpretation of the results, revision of the report, and have approved 295 
the final version of the manuscript. 296 
Included trials 297 
ATLANTIS A and B (Gregory Albers, James Grotta, Maarten Lansberg, Jean Marc Olivot); ECASS-1, 298 
ECASS-2, ECASS-3 (Erich Bluhmki, Werner Hacke, Markku Kaste, Kennedy Lees, Rüdiger von Kummer, 299 
Danilo Toni, Nils Wahlgren); EPITHET (Stephen Davis, Geoffrey Donnan, Mark Parsons); IST-3 (Peter 300 
Sandercock, Joanna Wardlaw, Richard Lindley, Geoff Cohen, William Whiteley); NINDS A and B 301 
(Thomas Brott, James Grotta, Patrick Lyden). 302 
STT Statistical Analysis Centre and Secretariat 303 
Colin Baigent, Lisa Blackwell, Erich Bluhmki, Kelly Davies, Jonathan Emberson, Heather Halls, Lisa 304 
Holland, George Howard, Clare Mathews, Samantha Smith, Kate Wilson. 305 
Declaration of interests 306 
CB, LB, and JE have not accepted fees, honoraria, or paid consultancies but are involved in clinical 307 
trials of lipid-modifying treatment funded by Merck to the University of Oxford, with the University 308 
the trial sponsor in all cases. KRL has received speaker fees from and has served on the data 309 
monitoring committee of trials for Boehringer Ingelheim; his department has received research 310 
grant support from Genentech. GA has received research grant support from Lundbeck, fees for 311 
consultancy and advisory board membership from Lundbeck, Covidien, Codman, and Genentech, 312 
fees for acting as an expert witness, and owns stock in iSchemaView. EB is employed by Boehringer 313 
Ingelheim. SD has received honoraria from Boehringer Ingelheim, EVER Pharma, and Sanofi and has 314 
received fees for consultancy and advisory board membership from Boehringer Ingelheim and 315 
Sanofi. GD has received research grant support from the NHMRC (Australia) and honoraria from 316 
Pfizer and Bristol-Myers Squibb. JG has received fees for consultancy and advisory board 317 
membership from Lundbeck. RvK has received speaker fees and honoraria from Penumbra and 318 
Lundbeck. RIL has received honoraria from Boehringer Ingelheim and Covidien. JMO has received 319 
speaker fees from Boehringer Ingelheim. MP has received travel support from Boehringer Ingelheim. 320 
DT has received speaker fees and fees for consultancy and advisory board membership from 321 
Boehringer Ingelheim and Bayer. KT has received research grant support from the Ministry of Health, 322 
Labour, and Welfare of Japan, and speaker fees from Mitsubishi Tanabe Pharma. JW has received 323 
research grant support from the UK Medical Research Council and from Boehringer Ingelheim to the 324 
University of Edinburgh for a research scanner bought more than 10 years ago. NW is chairman of 325 
SITS International which receives an unrestricted grant from Boehringer Ingelheim. WW has received 326 
research grant support from the UK Medical Research Council. PS has received honoraria for lectures 327 
which were paid to the department from Boehringer Ingelheim. WH has received research grant 328 
support from Boehringer Ingelheim, and speaker fees and fees for consultancy and advisory board 329 
membership from Boehringer Ingelheim. PL, TB, GC, GH, MKa, MKo, ML, NW, and GJdZ declare no 330 
competing interests. 331 
Acknowledgments 332 
This collaboration is coordinated by the Clinical Trial Service Unit & Epidemiological Studies Unit at 333 
the University of Oxford, UK. The Unit receives core funding from the UK Medical Research Council 334 
and the British Heart Foundation. This work also received support from the University of Glasgow 335 
and University of Edinburgh.  336 
  15 
Figure legends 337 
Figure 1: The effect within 7 days of alteplase on three types of intracerebral haemorrhage (ICH): 338 
parenchymal haemorrhage type 2 (PH-2), SITS-MOST haemorrhage, and fatal ICH. 339 
Figure 2: The effect of alteplase on SITS-MOST intracerebral haemorrhage at 24 to 36 hrs by time to 340 
treatment, age and stroke severity. 341 
Figure 3 The effect of alteplase on deaths following clinically significant intracerebral haemorrhage 342 
(fatal haemorrhage within 7 days or death following SITS-MOST haemorrhage), and all other deaths, 343 
during the first 90 days, overall and by period of follow up. 344 
Figure 4 Expected proportions in each category of modified Rankin score at 3—6 months, with or 345 
without alteplase given within 4.5 hours of symptom onset. mRS 0–1 indicates survival symptom-346 
free or with residual symptoms with no loss of activity; mRS 5-6 indicates bed-bound or dead at 3–6 347 
months. 348 
Figure 5 Expected stroke outcome at 3-6 months for groups of patients: i) not treated with alteplase; 349 
ii) treated with alteplase within 3 hours of stroke onset; and iii) treated with alteplase between 3 350 
and 4.5 hours after stroke onset. mRS 0–1 indicates survival symptom-free or residual symptoms 351 
with no loss of activity; mRS 5-6 indicates bed-bound or dead at 3–6 months. 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
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 360 
 361 
 362 
Research in Context 363 
Evidence before this study 364 
Meta-analyses have previously shown that alteplase increases the risk of intracerebral haemorrhage, 365 
but the extent to which the absolute excess risk differs by haemorrhage type, stroke severity, age, or 366 
treatment delay was uncertain, as was the balance between the risk of intracerebral haemorrhage 367 
and treatment benefit in different patients. We used individual participant data from 9 trials of 368 
alteplase versus control in the Stroke Thrombolysis Trialists’ Collaboration to provide meta-analyses 369 
of the available evidence. 370 
Added value of this study 371 
This study provides estimates of symptomatic intracerebral haemorrhage risk, and benefits due to 372 
alteplase, in patients grouped by stroke severity, age and treatment delay. With the individual 373 
participant data, we were able to adjust for complex inter-correlations between variables to produce 374 
reliable estimates of absolute treatment effects.  375 
Implications of all the available evidence  376 
The absolute benefits of alteplase decline with treatment delay, and the absolute harms due to 377 
alteplase (from intracranial haemorrhage) increase with stroke severity. When delivered within 4.5 378 
hours, the proportion of patients experiencing a good outcome exceeds those dying from 379 
intracranial haemorrhage. However, because the risk of haemorrhage is highest in those with the 380 
most severe stroke, prompt treatment of these patients is especially important. These absolute risk 381 
estimates will be useful to communicate the effects of alteplase to patients, families and clinicians.  382 
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Table 1: Baseline characteristics of participating trials 
 
Variable NINDS A
11
 NINDS B
11
 ECASS I
7
 ECASS II
12
 ATLANTIS A
15
 ATLANTIS B
14
 ECASS III
13
 EPITHET
10
 IST-3
8
 TOTAL 
Number randomized 291 333 620 800 142 613 821 101 3035 6756 
Alteplase 144 (49%) 168 (50%) 313 (50%) 409 (51%) 71 (50%) 301 (49%) 418 (51%) 52 (51%) 1515 (50%) 3391 (50%) 
Control 147 (51%) 165 (50%) 307 (50%) 391 (49%) 71 (50%) 312 (51%) 403 (49%) 49 (49%) 1520 (50%) 3365 (50%) 
Treatment delay (hours) 2.0 (0.6) 2.0 (0.6) 4.4 (1.1) 4.3 (1.1) 4.3 (1.1) 4.4 (0.8) 4.0 (0.4) 4.9 (0.8) 4.2 (1.2) 4.0 (1.2) 
>0, 3 290 (>99%) 333 (100%) 87 (14%) 158 (20%) 22 (15%) 39 (6%) - - 620 (20%) 1549 (23%) 
>3, 4.5 1 (<1%) - 233 (38%) 265 (33%) 53 (37%) 249 (41%) 788 (96%) 31 (31%) 1148 (38%) 2768 (41%) 
>4.5 - - 295 (48%) 370 (46%) 67 (47%) 321 (52%) 6 (1%) 69 (68%) 1266 (42%) 2394 (35%) 
Missing - - 5 (1%) 7 (1%) - 4 (1%) 27 (3%) 1 (1%) 1 (<1%) 45 (1%) 
Age (years) 66 (11) 68 (12) 65 (12) 66 (11) 66 (13) 66 (11) 65 (12) 72 (13) 77 (12) 71 (13) 
80 279 (96%) 289 (87%) 615 (>99%) 792 (99%) 142 (100%) 608 (>99%) 805 (98%) 76 (75%) 1418 (47%) 5024 (74%) 
>80 12 (4%) 44 (13%) 5 (1%) 8 (1%) - 3 (<1%) 15 (2%) 25 (25%) 1617 (53%) 1729 (26%) 
Missing - - - - - 2 (<1%) 1 (<1%) - - 3 (<1%) 
Stroke severity (NIHSS) 14 (7) 15 (7) 12 (6) 12 (6) 13 (7) 11 (6) 10 (5) 13 (6) 12 (7) 12 (7) 
>0, 4 16 (5%) 13 (4%) 34 (5%) 47 (6%) 10 (7%) 47 (8%) 98 (12%) 1 (1%) 400 (13%) 666 (10%) 
>4, 10 78 (27%) 98 (29%) 189 (30%) 339 (42%) 57 (40%) 279 (46%) 389 (47%) 40 (40%) 1064 (35%) 2533 (37%) 
>10, 15 68 (23%) 63 (19%) 183 (30%) 232 (29%) 28 (20%) 128 (21%) 163 (20%) 22 (22%) 601 (20%) 1488 (22%) 
>15, 21 76 (26%) 78 (23%) 146 (24%) 113 (14%) 25 (18%) 106 (17%) 142 (17%) 29 (29%) 618 (20%) 1333 (20%) 
>21 45 (15%) 74 (22%) 28 (5%) 43 (5%) 20 (14%) 33 (5%) 18 (2%) 9 (9%) 352 (12%) 622 (9%) 
Missing 8 (3%) 7 (2%) 40 (6%) 26 (3%) 2 (1%) 20 (3%) 11 (1%) - * 114 (2%) 
Female 120 (41%) 142 (43%) 231 (37%) 331 (41%) 45 (32%) 250 (41%) 325 (40%) 43 (43%) 1570 (52%) 3057 (45%) 
History of hypertension 188 (65%) 220 (66%) 258 (42%) 412 (52%) 87 (61%) 364 (59%) 514 (63%) 71 (70%) 1954 (64%) 4068 (60%) 
History of stroke 49 (17%) 34 (10%) 83 (13%) 158 (20%) 31 (22%) 89 (15%) 89 (11%) 11 (11%) 699 (23%) 1243 (18%) 
History of diabetes mellitus 64 (22%) 67 (20%) 81 (13%) 169 (21%) 27 (19%) 130 (21%) 129 (16%) 23 (23%) 388 (13%) 1078 (16%) 
History of atrial fibrillation 55 (19%) 60 (18%) 113 (18%) 188 (24%) 37 (26%) 97 (16%) 108 (13%) 42 (42%) 914 (30%) 1614 (24%) 
Antiplatelet use 78 (27%) 93 (28%) 87 (14%) 196 (25%) 59 (42%) 211 (34%) 201 (24%) 30 (30%) 1306 (43%) 2261 (33%) 
Weight (kg) 78 (17) 78 (19) 74 (12) 75 (14) 80 (20) 79 (18) 78 (15) 75 (19) 72 (15) 75 (16) 
Systolic blood pressure (mmHg) 154 (21) 152 (21) 154 (23) 152 (21) 152 (24) 152 (21) 153 (21) 148 (19) 155 (24) 154 (22) 
Diastolic blood pressure (mmHg) 85 (13) 85 (14) 87 (13) 84 (13) 81 (14) 82 (14) 84 (14) 78 (13) 82 (15) 83 (14) 
 
Categorical data presented as n (%), continuous data presented as mean (SD). NINDS=National Institute of Neurological Disorders and Stroke; ECASS=European Cooperative Acute Stroke Study; 
ATLANTIS=Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke; EPITHET=Echoplanar Imaging Thrombolytic Evaluation Trial; IST=International Stroke Trial. *In IST-3, 244 
patients had their baseline NIHSS score predicted from other measurements recorded at their baseline assessment. Ignoring these patients, the numbers of IST-3 patients in each category of baseline 
NIHSS score above would be 385, 972, 531, 559 and 344 respectively. 
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Figure 1: The effect within 7 days of alteplase on three types of intracerebral
haemorrhage (ICH): parenchymal haemorrhage type 2 (PH−2), SITS−MOST
haemorrhage, and fatal ICH
Alteplase
(n=3391)
Control
(n=3365) Odds ratio (95% CI)*
* Estimated from a trial−stratified logistic regression model adjusted only for treatment allocation
PH−2 231 (6.8%) 44 (1.3%) 5.55 (4.01 − 7.70)
SITS−MOST 124 (3.7%) 19 (0.6%) 6.67 (4.11 − 10.84)
Fatal ICH within 7 days 91 (2.7%) 13 (0.4%) 7.14 (3.98 − 12.79)
Figure
Click here to download Figure: 2016-04-28 Figures 1-5.pdf
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Control
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Figure 2: The effect of alteplase on SITS−MOST intracerebral haemorrhage at 24 to 36 hrs by time to treatment, age and stroke severity
Alteplase
worse
Alteplase
better
χ1
2
 = 0.31
(p=0.58)
χ1
2
 = 0.04
(p=0.83)
χ1
2
 = 1.19
(p=0.27)
Treatment delay
 ≤ 3 hours 30/787 (3.8%) 3/762 (0.4%)
>3, ≤ 4.5 hours 43/1375 (3.1%) 8/1437 (0.6%)
>4.5 hours 51/1229 (4.1%) 8/1166 (0.7%)
Age
 ≤ 80 years 88/2512 (3.5%) 14/2515 (0.6%)
>80 years 36/879 (4.1%) 5/850 (0.6%)
Baseline NIHSS
0−4 6/345 (1.7%) 1/321 (0.3%)
5−10 40/1281 (3.1%) 5/1252 (0.4%)
11−15 37/794 (4.7%) 2/808 (0.2%)
16−21 26/662 (3.9%) 8/671 (1.2%)
≥ 22 15/309 (4.9%) 3/313 (1.0%)
* For each of the three baseline characteristics shown, the odds ratio subgroup estimates shown are derived from a single trial−stratified logistic regression model which allows
for separate estimation of the OR in each of the subgroups after adjustment for the other two baseline characteristics (but not possible interactions with those characteristics).
The overall effect in all patients (indicated by the open diamond) is the trial−stratified logistic regression estimate adjusted only for treatment allocation.
The absolute excess risk (and its 95% CI) for each subgroup is estimated by applying the odds ratio seen among all randomised patients (or its confidence limits) to the average
expected risk among control−allocated patients for that subgroup (estimated from a logistic regression model among all participants adjusted for trial, treatment allocation,
the subgroup of interest and average levels of the other two baseline characteristics).
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Figure 3: Effect of alteplase on: a) deaths preceded by clinically significant
intracerebral haemorrhage (SITS−MOST or fatal haemorrhage within 7 days);
and b) all other deaths, within the first 90 days
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Figure 4: Expected proportions in each category of modified Rankin score at 3—6 months,
with or without alteplase given within 4.5 hours of symptom onset (mean 3 hrs 20 min)
mRS 0/1='Excellent' outcome; In IST−3, 125 (4.1%) patients died between 3 and 6 months. For comparability of mRS 6 between IST−3
and the other trials (which had 3 month mRS), these patients were reassigned an mRS of 5 for this analysis.
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Figure 5: EXPECTED stroke outcome at 3−6 months for groups of
patients: i) not treated with alteplase; ii) treated with alteplase within 3
hours of stroke onset; and iii) treated with alteplase between 3 and
4.5 hours after stroke onset.
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Each 10 x 10 grid represents 100 hypothetical patients who have experienced a stroke with severity
0−4 NIHSS points (top row), 5−15 points (middle row) or 16+ points (bottom row). Each circle in each
grid represents a single patient with the colour of the circle reflecting their expected mRS outcome at
3−6 months if: a) not given alteplase (left column); b) given alteplase within 3 hours (middle column);
or c) given alteplase between 3 and 4.5 hours (right column). 
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Webfigure 1: Effect of alteplase on intracerebral haemorrhage in each trial
Where estimable, individual trial estimates above correspond to the simple odds ratio and its 95% confidence interval. The summary diamonds, and their 95% CIs,
are derived from trial−stratified logistic regression models (which allow trials with zero events in the control arm to contribute information). There was no evidence
that the proportional effect of allocation to alteplase on ICH differed between the placebo−controlled trials and IST−3 (p=0.76 for PH−2 within 7 days, p=0.72 for
SITS−MOST haemorrhage and p=0.61 for fatal ICH within 7 days. Nor was there any evidence of significant heterogenity between all 9 trials (test for
trial−by−treatment interaction: p=0.57 for PH−2 within days, p=0.87 for SITS−MOST haemorrhage and p=0.88 for fatal ICH within 7 days).
PH−2 within 7 days
Alteplase Control Odds ratio (95% CI)Trial
Placebo−controlled
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2 (1.2%)
8 (2.6%)
3 (0.8%)
0 (0.0%)
2 (0.6%)
4 (1.0%)
0 (0.0%)
25 (1.6%)
Alteplase
better
Alteplase
worse
97 (5.2%) 19 (1.0%) 5.24
(3.19 − 8.60)
5.80
(3.76 − 8.95)
All patients 5.55
(4.01 − 7.70)
231 (6.8%) 44 (1.3%)
1 4 16
SITS−MOST haemorrhage
Alteplase Control Odds ratio (95% CI)
4 (2.8%)
3 (1.8%)
11 (3.5%)
24 (5.9%)
3 (4.2%)
8 (2.7%)
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0 (0.0%)
1 (0.3%)
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worse
65 (3.5%) 9 (0.5%) 7.29
(3.62 − 14.69)
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(4.11 − 10.84)
124 (3.7%) 19 (0.6%)
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Fatal ICH within 7 days
Alteplase Control Odds ratio (95% CI)
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Webfigure 2: Treatment−modifying effects of time to treatment, age and stroke
severity on parenchymal haemorrhage type 2 within 7 days
The solid line on each plot shows how the estimated odds ratio associated with allocation to alteplase varies with,
respectively, time, age and baseline NIHSS, so its slope provides a test for interaction between that characteristic
and allocation to alteplase. Each panel is adjusted for treatment delay, age, and baseline NIHSS (as linear main
effects), and all three treatment−interaction terms (ie, all three panels derive from the same regression model).
The odds ratio in each panel corresponds to patients with AVERAGE levels of the other 2 baseline characteristics. The
OR for alteplase was 6.26 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours).
The significance of each interaction, as well as the global test of all interactions, is tested by comparing the change in
deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test).
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Webfigure 3: Treatment−modifying effects of time to treatment, age and stroke
severity on SITS−MOST intracerebral haemorrhage at 24−36 hours
The solid line on each plot shows how the estimated odds ratio associated with allocation to alteplase varies with,
respectively, time, age and baseline NIHSS, so its slope provides a test for interaction between that characteristic
and allocation to alteplase. Each panel is adjusted for treatment delay, age, and baseline NIHSS (as linear main
effects), and all three treatment−interaction terms (ie, all three panels derive from the same regression model).
The odds ratio in each panel corresponds to patients with AVERAGE levels of the other 2 baseline characteristics. The
OR for alteplase was 6.94 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours).
The significance of each interaction, as well as the global test of all interactions, is tested by comparing the change in
deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test).
−2 −1 0 1
SDs from mean
Age (years)
O
dd
s 
ra
tio
 (9
5%
 C
I)
1
2
5
10
20
40
50 60 70 80 90
Interaction:
χ1
2
=0.22 (p=0.64)
Global test of all interactions:χ3
2
=1.07 (p=0.79)
−1 0 1
SDs from mean
Baseline NIHSS
O
dd
s 
ra
tio
 (9
5%
 C
I)
1
2
5
10
20
40
0 5 10 15 20 25
Interaction:
χ2
2
=0.87 (p=0.65)
−1 0 1
SDs from mean
Page 4 of 10
Time to treatment (hours)
O
dd
s 
ra
tio
 (9
5%
 C
I)
1
2
5
10
20
40
1 2 3 4 5 6
Interaction:
χ1
2
=0.08 (p=0.78)
Webfigure 4: Treatment−modifying effects of time to treatment, age and stroke
severity on fatal intracerebral haemorrhage within 7 days
The solid line on each plot shows how the estimated odds ratio associated with allocation to alteplase varies with,
respectively, time, age and baseline NIHSS, so its slope provides a test for interaction between that characteristic
and allocation to alteplase. Each panel is adjusted for treatment delay, age, and baseline NIHSS (as linear main
effects), and all three treatment−interaction terms (ie, all three panels derive from the same regression model).
The odds ratio in each panel corresponds to patients with AVERAGE levels of the other 2 baseline characteristics. The
OR for alteplase was 6.63 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours).
The significance of each interaction, as well as the global test of all interactions, is tested by comparing the change in
deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test).
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Webfigure 5: The effect of alteplase on parenchymal haemorrhage type 2 within 7 days by time to treatment, age and stroke severity
Alteplase
worse
Alteplase
better
χ1
2
 = 0.00
(p=0.96)
χ1
2
 = 0.41
(p=0.52)
χ1
2
 = 2.78
(p=0.10)
Treatment delay
 ≤ 3 hours 51/787 (6.5%) 7/762 (0.9%)
>3, ≤ 4.5 hours 82/1375 (6.0%) 21/1437 (1.5%)
>4.5 hours 98/1229 (8.0%) 16/1166 (1.4%)
Age
 ≤ 80 years 153/2512 (6.1%) 27/2515 (1.1%)
>80 years 78/879 (8.9%) 17/850 (2.0%)
Baseline NIHSS
0−4 10/345 (2.9%) 1/321 (0.3%)
5−10 65/1281 (5.1%) 8/1252 (0.6%)
11−15 63/794 (7.9%) 7/808 (0.9%)
16−21 54/662 (8.2%) 21/671 (3.1%)
≥ 22 39/309 (12.6%) 7/313 (2.2%)
* For each of the three baseline characteristics shown, the odds ratio subgroup estimates shown are derived from a single trial−stratified logistic regression model which allows
for separate estimation of the OR in each of the subgroups after adjustment for the other two baseline characteristics (but not possible interactions with those characteristics).
The overall effect in all patients (indicated by the open diamond) is the trial−stratified logistic regression estimate adjusted only for treatment allocation.
The absolute excess risk (and its 95% CI) for each subgroup is estimated by applying the odds ratio seen among all randomised patients (or its confidence limits) to the average
expected risk among control−allocated patients for that subgroup (estimated from a logistic regression model among all participants adjusted for trial, treatment allocation,
the subgroup of interest and average levels of the other two baseline characteristics).
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Webfigure 6: The effect of alteplase on fatal intracerebral haemorrhage within 7 days by time to treatment, age and stroke severity
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χ1
2
 = 0.21
(p=0.65)
Treatment delay
 ≤ 3 hours 22/787 (2.8%) 2/762 (0.3%)
>3, ≤ 4.5 hours 35/1375 (2.5%) 7/1437 (0.5%)
>4.5 hours 34/1229 (2.8%) 4/1166 (0.3%)
Age
 ≤ 80 years 59/2512 (2.3%) 9/2515 (0.4%)
>80 years 32/879 (3.6%) 4/850 (0.5%)
Baseline NIHSS
0−4 3/345 (0.9%) 0/321 (0.0%)
5−10 20/1281 (1.6%) 5/1252 (0.4%)
11−15 23/794 (2.9%) 1/808 (0.1%)
16−21 24/662 (3.6%) 5/671 (0.7%)
≥ 22 21/309 (6.8%) 2/313 (0.6%)
* For each of the three baseline characteristics shown, the odds ratio subgroup estimates shown are derived from a single trial−stratified logistic regression model which allows
for separate estimation of the OR in each of the subgroups after adjustment for the other two baseline characteristics (but not possible interactions with those characteristics).
The overall effect in all patients (indicated by the open diamond) is the trial−stratified logistic regression estimate adjusted only for treatment allocation.
The absolute excess risk (and its 95% CI) for each subgroup is estimated by applying the odds ratio seen among all randomised patients (or its confidence limits) to the average
expected risk among control−allocated patients for that subgroup (estimated from a logistic regression model among all participants adjusted for trial, treatment allocation,
the subgroup of interest and average levels of the other two baseline characteristics).
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Webfigure 7a: Expected proportions in each category of modified Rankin score at 3—6 months,
with or without alteplase given within 3 hours of symptom onset (mean 2 hrs 20 min)
mRS 0/1='Excellent' outcome; In IST−3, 125 (4.1%) patients died between 3 and 6 months. For comparability of mRS 6 between IST−3
and the other trials (which had 3 month mRS), these patients were reassigned an mRS of 5 for this analysis. Page 8 of 10
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Webfigure 7b: Expected proportions in each category of modified Rankin score at 3—6 months,
with or without alteplase given within 3−4.5 hours of symptom onset (mean 3 hrs 50 min)
mRS 0/1='Excellent' outcome; In IST−3, 125 (4.1%) patients died between 3 and 6 months. For comparability of mRS 6 between IST−3
and the other trials (which had 3 month mRS), these patients were reassigned an mRS of 5 for this analysis. Page 9 of 10
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Webfigure 8: Effect of alteplase on: a) deaths preceded by PH−2 haemorrhage;
and b) all other deaths, within the first 90 days
Follow−up, day
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Control
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